Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) News

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): $110.37

0.88 (+0.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HZNP News Items

HZNP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HZNP News Highlights

  • HZNP's 30 day story count now stands at 16.
  • Over the past 26 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • RARE, BODY and EYE are the most mentioned tickers in articles about HZNP.

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis

DUBLIN, September 21, 2021--Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce two winning solutions of this year’s Horizon Prize, ThinkGenetic Inc. and Congenica. The winners will share $150,000 in funding to continue evolving their solutions for reducing the time it takes to be diagnosed with a rare disease.

Yahoo | September 21, 2021

HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and validation of two novel gout drug targets in accordance with the Horizon exclusive drug discovery agreement e

Yahoo | September 21, 2021

Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®

DUBLIN, September 16, 2021--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®. The Best Workplaces for Women award spotlights the top U.S. companies who have made a commitment to fostering equity in the workplace by ensuring women employees can reach their full potential.

Yahoo | September 16, 2021

Cystic Fibrosis Therapeutics Market revenue to cross USD 26.6 Bn by 2027: Global Market Insights Inc.

Major cystic fibrosis therapeutics market players include Vertex Pharmaceuticals Incorporated, Roche, Nestle Health Science, Abbvie, Viatris Inc., Horizon Therapeutics plc, Gilead Life Sciences, Chiesi Farmaceutici, Pharmaxis Ltd, and Teva Pharmaceuticals. Major cystic fibrosis therapeutics market players include Vertex Pharmaceuticals Incorporated, Roche, Nestle Health Science, Abbvie, Viatris Inc., Horizon Therapeutics plc, Gilead Life Sciences, Chiesi Farmaceutici, Pharmaxis Ltd, and Teva Pharmaceuticals.

Intrado Digital Media | September 8, 2021

Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Horizon initiates a clinical trial evaluating TEPEZZA® (teprotumumab-trbw) for the treatment for chronic (inactive) Thyroid Eye Disease (TED).

Business Wire | September 7, 2021

Are Strong Financial Prospects The Force That Is Driving The Momentum In Horizon Therapeutics Public Limited Company's NASDAQ:HZNP) Stock?

Horizon Therapeutics (NASDAQ:HZNP) has had a great run on the share market with its stock up by a significant 23% over...

Yahoo | September 6, 2021

Osteoarthritis Therapeutics Market to Attain Higher Growth as Players Trying Identify Untapped Opportunities, Key Players - Sanofi (France), Horizon Therapeutics (Ireland), Johnson & Johnson (US), GlaxoSmithKline Plc (UK)

"Global Osteoarthritis Therapeutics Market Analysis to 2027" is a detailed and comprehensive report on the market, with a special focus on global market trends. market report provides the market overview, including detailed segmentation and sub-segments. It is expected that the

OpenPR | September 1, 2021

Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®

DUBLIN, September 01, 2021--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to PEOPLE's 100 Companies That Care® 2021 list for the third year by PEOPLE and Great Place to Work®. The PEOPLE Companies that Care list spotlights the top U.S. companies who have succeeded in business while also demonstrating outstanding respect, care and concern for their employees, their communities and the environment. The list will be featured in the Sept. 13, 2021 print issue of PEOP

Yahoo | September 1, 2021

15 Best Pharmaceutical Stocks to Invest In

In this article, we discuss the 15 best pharmaceutical stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Pharmaceutical Stocks to Invest In. After the Covid-19 pandemic hit, the pharmaceutical industry rapidly began the process of developing and testing vaccines and medicines for […]

Yahoo | August 31, 2021

Argininosuccinic Aciduria Market Inherited Growth Prospects by 2021-28| Horizon Therapeutics, Acer Therapeutics, Evox Therapeutics

Argininosuccinic aciduria is a rare genetic disorder characterized by deficiency or lack of the enzyme argininosuccinate lyase (ASL). This enzyme is one of six enzymes that play a role in the breakdown and removal of nitrogen from the body, a

OpenPR | August 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 2.4103 seconds.